Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 11/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20600606 | 0.91 | LPL (0.37) | LPLLIPGHSD17B10ALDH1A1F11 | |
| SCHEMBL530239 | 0.88 | LPL (0.41) | LPLLIPGF11CA1CA2 | |
| SCHEMBL529553 | 0.85 | MEN1 (0.39) | LPLLIPGHSD17B10ALDH1A1ALOX12 | |
| SCHEMBL31035194 | 0.84 | ERN1 (0.49) | LPLLIPGALDH1A1F11CA1 | |
| SCHEMBL4789211 | 0.83 | LPL (0.42) | LPLLIPGALDH1A1F11CA1 | |
| SCHEMBL2204718 | 0.82 | LPL (0.41) | LPLLIPGF11CA1CA2 | |
| SCHEMBL177571 | 0.82 | LPL (0.41) | LPLLIPGF11HIF1ACA1 | |
| SCHEMBL12632055 | 0.80 | LPL (0.40) | LPLLIPGALDH1A1CYP3A4F11 | |
| SCHEMBL2523103 | 0.80 | LPL (0.47) | LPLLIPGF11CA1CA2 | |
| SCHEMBL21246704 | 0.80 | WDR5 (0.36) | LIPGF11SMN1; SMN2HIF1ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12195467-B2 | Compound having TrkA inhibitory activity and pharmaceutical composition, for preventing or alleviating pain, containing same as active ingredient | JBKLAB CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| EP-3819298-B1 | COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT | JBKLAB CO LTD (KR) | 2024-10-30 | — | — | EP | disclosed |
| US-20240207271-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, CONTAINING 2,6-DICHLORO-4-(4-(4-HYDROXYCYCLOHEXYLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)PHENOL AS ACTIVE INGREDIENT | JBKLAB CO.,LTD. (KR) | 2024-06-27 | — | — | US | disclosed |
| US-20240207271-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, CONTAINING 2,6-DICHLORO-4-(4-(4-HYDROXYCYCLOHEXYLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)PHENOL AS ACTIVE INGREDIENT | JBKLAB CO.,LTD. (KR) | 2024-06-27 | — | — | US | disclosed |
| CN-114671815-B | Aryl barbiturates compound and preparation method and application thereof | 中国医学科学院药物研究所 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-117355305-A | Pharmaceutical composition for preventing, improving or treating cancer comprising 2, 6-dichloro-4- (4- (4-hydroxycyclohexylamino) -7H-pyrrolo [2,3-D ] pyrimidin-5-yl) phenol as active ingredient | 株式会社张峰根硏究所 | 2024-01-05 | — | — | CN | disclosed |
| CN-112533919-B | Compounds having TRKA inhibitory activity and pharmaceutical compositions for preventing or treating pain comprising the same as active ingredient | 株式会社张峰根硏究所 | 2023-06-16 | — | — | CN | disclosed |
| WO-2022216945-A1 | MACROCYCLIC MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| WO-2013109388-A2 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-25 | — | — | WO | disclosed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207271-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, CONTAINING 2,6-DICHLORO-4-(4-(4-HYDROXYCYCLOHEXYLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)PHENOL AS ACTIVE INGREDIENT | TOP2A, TP53, TOP2B | LPL 2124/4885LIPG 413/4885HSD17B10 1103/4885 |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NEK1, NEK5 | LPL 4259/4885LIPG 3288/4885HSD17B10 3381/4885 |
| US-12195467-B2 | Compound having TrkA inhibitory activity and pharmaceutical composition, for preventing or alleviating pain, containing same as active ingredient | NGF, OPRL1, TRPV1 | LPL 2441/4885LIPG 3946/4885HSD17B10 3734/4885 |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NADK, NEK1 | LPL 4636/4885LIPG 4436/4885HSD17B10 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.